Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11411328 | 0.81 | EPHX2 (0.46) | APPPOLHKDM4EMEN1MAPT | |
| SCHEMBL4175201 | 0.77 | POLH (0.76) | APPPOLHKDM4EMEN1MAPT | |
| SCHEMBL31236662 | 0.77 | POLH (0.76) | APPPOLHKDM4EMEN1MAPT | |
| SCHEMBL4157261 | 0.77 | SRC (0.44) | APPPOLHKDM4EMEN1MAPT | |
| SCHEMBL4169452 | 0.74 | ALOX5 (0.49) | POLHALOX5 | |
| SCHEMBL31250385 | 0.74 | KDM4E (0.56) | APPPOLHKDM4EMEN1MAPT | |
| SCHEMBL16882942 | 0.74 | KDM4E (0.68) | APPPOLHKDM4EMEN1MAPT | |
| SCHEMBL4165925 | 0.74 | ALOX5 (0.50) | POLHALOX5 | |
| SCHEMBL4155997 | 0.74 | ALOX5 (0.50) | POLHALOX5 | |
| SCHEMBL4164333 | 0.74 | ALOX5 (0.50) | POLHALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2009-05-21 | — | — | US | claimed |
| EP-0570475-A1 | PHARMACEUTICAL PREPARATION FOR THE THERAPY OF TUMORS, PARTICULARLY OVARIAN AND HAEMOPOIETIC SYSTEM TUMORS, CONTAINING QUERCETIN COMPOUNDS AS ACTIVE SUBSTANCES | ROMEO, Francesco (IT) | 1993-11-24 | — | — | EP | claimed |
| WO-1992013851-A1 | PHARMACEUTICAL PRODUCT FOR THE THERAPY OF TUMORS, PARTICULARLY OVARIAN AND HAEMOPOIETIC SYSTEM TUMORS, CONTAINING QUERCETIN COMPOUNDS AS ACTIVE SUBSTANCES | ROMEO, FRANCESCO (IT) | 1992-08-20 | — | — | WO | claimed |
| US-11458200-B2 | Constructs, agents, and methods for facilitated ablation of cardiac tissue | Sauer, William (US) | 2022-10-04 | — | — | US | disclosed |
| US-11229622-B2 | Cosmetological and pharmaceutical composition based on combinatorial quercetin derivative | FARBER BORIS (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210205263-A1 | COSMETOLOGICAL AND PHARMACEUTICAL COMPOSITION BASED ON COMBINATORIAL QUERCETIN DERIVATIVE | FARBER BORIS SLAVINOVICH (RU) | 2021-07-08 | — | — | US | disclosed |
| US-20190328877-A1 | Constructs, Agents, and Methods for Facilitated Ablation of Cardiac Tissue | NGUYEN, DUY | 2019-10-31 | — | — | US | disclosed |
| EP-3451959-A1 | CONSTRUCTS, AGENTS, AND METHODS FOR FACILITATED ABLATION OF CARDIAC TISSUE | The Regents of The University of Colorado, A Body Corporate (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192804-A1 | CONSTRUCTS, AGENTS, AND METHODS FOR FACILITATED ABLATION OF CARDIAC TISSUE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-0524744-B1 | Base board for printed circuit board | MITSUBISHI GAS CHEMICAL CO (JP) | 1995-06-21 | — | — | EP | disclosed |
| US-5266385-A | For inspection of printed circuit patterns | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1993-11-30 | — | — | US | disclosed |
| EP-0570475-A1 | PHARMACEUTICAL PREPARATION FOR THE THERAPY OF TUMORS, PARTICULARLY OVARIAN AND HAEMOPOIETIC SYSTEM TUMORS, CONTAINING QUERCETIN COMPOUNDS AS ACTIVE SUBSTANCES | ROMEO, Francesco (IT) | 1993-11-24 | — | — | EP | disclosed |
| EP-0570475-A1 | PHARMACEUTICAL PREPARATION FOR THE THERAPY OF TUMORS, PARTICULARLY OVARIAN AND HAEMOPOIETIC SYSTEM TUMORS, CONTAINING QUERCETIN COMPOUNDS AS ACTIVE SUBSTANCES | ROMEO, Francesco (IT) | 1993-11-24 | — | — | EP | disclosed |
| EP-0524744-A1 | Base board for printed circuit board | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1993-01-27 | — | — | EP | disclosed |
| WO-1992013851-A1 | PHARMACEUTICAL PRODUCT FOR THE THERAPY OF TUMORS, PARTICULARLY OVARIAN AND HAEMOPOIETIC SYSTEM TUMORS, CONTAINING QUERCETIN COMPOUNDS AS ACTIVE SUBSTANCES | ROMEO, FRANCESCO (IT) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992013851-A1 | PHARMACEUTICAL PRODUCT FOR THE THERAPY OF TUMORS, PARTICULARLY OVARIAN AND HAEMOPOIETIC SYSTEM TUMORS, CONTAINING QUERCETIN COMPOUNDS AS ACTIVE SUBSTANCES | ROMEO, FRANCESCO (IT) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | CAT, NQO1, GPX4 | APP 4633/4885POLH 3392/4885KDM4E 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.